Clinical implications of ageing for the management of IBD

Nature Reviews Gastroenterology and Hepatology

Volumn 11, Issue 2, 2014, Pages 128-138

  Ha, Christina Y ^a   Katz, Seymour ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGED; AGED, 80 AND OVER; AGING; ALGORITHMS; CAREGIVERS; DISEASE MANAGEMENT; GERIATRIC ASSESSMENT; HEALTH CARE COSTS; HUMANS; INFLAMMATORY BOWEL DISEASES; TREATMENT OUTCOME;

6 MERCAPTOPURINE DERIVATIVE; AMINOSALICYLIC ACID DERIVATIVE; C REACTIVE PROTEIN; CORTICOSTEROID; MESALAZINE; NICOTINE; PLACEBO; PREDNISONE; TUMOR NECROSIS FACTOR INHIBITOR;

AGED; AGING; BACTERIAL PNEUMONIA; CATARACT; COMORBIDITY; CROHN DISEASE; DIABETES MELLITUS; DISEASE ACTIVITY; DIZZINESS; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG COST; DRUG DOSE ESCALATION; DRUG EXCRETION; DRUG MEGADOSE; DRUG METABOLISM; DRUG MONITORING; DRUG WITHDRAWAL; FRACTURE; GERIATRIC PATIENT; GLAUCOMA; HEADACHE; HERPES ZOSTER; HIGH RISK PATIENT; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTENSION; IMMUNE DEFICIENCY; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INFLAMMATORY BOWEL DISEASE; INTESTINE FLORA; LEUKEMIA; LEUKOPENIA; LOW DRUG DOSE; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; MALIGNANT NEOPLASTIC DISEASE; NAUSEA; NEPHROTOXICITY; NON MELANOMA SKIN CANCER; OSTEOPOROSIS; POLYPHARMACY; REMISSION; RESPIRATORY TRACT INFECTION; REVIEW; RHEUMATOID ARTHRITIS; SLEEP DISORDER; SMOKING CESSATION; TREMOR; ULCERATIVE COLITIS;

EID: 84893754436     PISSN: 17595045     EISSN: 17595053     Source Type: Journal    
DOI: 10.1038/nrgastro.2013.241     Document Type: Review

References (124)

1. Molodecky, N. A. et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology 142, 46-54 (2012).
2. Loftus, C. G. et al. Update on the incidence and prevalence of Crohns Disease and Ulcerative Colitis in Olmsted County, Minnesota, 1940-2000. Inflamm. Bowel Dis. 13, 254-261 (2007).
3. Kappelman, M. D. et al. The prevalence and geographic distribution of Crohns disease and ulcerative colitis in the United States. Clin. Gastroenterol. Hepatol. 5, 1424-1429 (2007).
4. Administration on Aging. 2010 Census Data on Aging [online], http://www.aoa.gov/aoaroot/aging-statistics/Census-Population/census2010/Index. aspx (2011).
5. Loftus, E. V. Jr et al. Crohns disease in Olmsted County, Minnesota, 1940-1993: incidence, prevalence, and survival. Gastroenterology 114, 1161-1168 (1998).
6. Loftus, E. V. Jr et al. Ulcerative colitis in Olmsted County, Minnesota, 1940-1993: incidence, prevalence, and survival. Gut 46, 336-343 (2000).
7. Charpentier, C. et al. Natural history of elderly-onset inflammatory bowel disease: a population-based cohort study. Gut http://dx.doi.org/10.1136/ gutjnl-2012-303864.
8. Katz, S. &Pardi, D. S. Inflammatory bowel disease of the elderly: frequently asked questions (FAQs). Am. J. Gastroenterol. 106, 1889-1897 (2011).
9. The National Institute of Diabetes and Digestive and Kidney Diseases. Burden of digestive diseases in the United States, 2008. NIH Publication No. 09-6443 [online], http://www2.niddk.nih.gov/AboutNIDDK/ ReportsAndStrategicPlanning/ (2013).
10. Ananthakrishnan, A. N., McGinley, E. L. &Binion, D. G. Inflammatory bowel disease in the elderly is associated with worse outcomes: a national study of hospitalizations. Inflamm. Bowel Dis. 15, 182-189 (2009).
11. Ananthakrishnan, A. N., McGinley, E. L. &Binion, D. G. Excess hospitalisation burden associated with Clostridium difficile in patients with inflammatory bowel disease. Gut 57, 205-210 (2008).
12. Lichtenstein, G. R. et al. Serious infection and mortality in patients with Crohns disease: more than 5 years of follow-up in the TREAT registry. Am. J. Gastroenterol. 107, 1409-1422 (2012).
13. Nguyen, G. C. &Sam, J. Rising prevalence of venous thromboembolism and its impact on mortality among hospitalized inflammatory bowel disease patients. Am. J. Gastroenterol. 103, 2272-2280 (2008).
14. Baumgart, D. C. &Carding, S. R. Inflammatory bowel disease: cause and immunobiology. Lancet 369, 1627-1640 (2007).
15. Ordas, I. et al. Ulcerative colitis. Lancet 380, 1606-1619 (2012).
16. Baumgart, D. C. &Sandborn, W. J. Crohns disease. Lancet 380, 1590-1605 (2012).
17. Britton, E. &McLaughlin, J. T. Ageing and the gut. Proc. Nutr. Soc. 72, 173-177 (2013).
18. Linton, P. J. &Dorshkind, K. Age-related changes in lymphocyte development and function. Nat. Immunol. 5, 133-139 (2004).
19. Fessler, J. et al. The impact of aging on regulatory T-cells. Front. Immunol. 4, 231 (2013).
20. Clegg, A. et al. Frailty in elderly people. Lancet 381, 752-762 (2013).
21. Cambier, J. Immunosenescence: a problem of lymphopoiesis, homeostasis, microenvironment, and signaling. Immunol. Rev. 205, 5-6 (2005).
22. Schiffrin, E. J. et al. The inflammatory status of the elderly: the intestinal contribution. Mutat. Res. 690, 50-56 (2010).
23. Biagi, E. et al. Aging of the human metaorganism: the microbial counterpart. Age 34, 247-267 (2012).
24. Zwielehner, J. et al. Combined PCR-DGGE fingerprinting and quantitative-PCR indicates shifts in fecal population sizes and diversity of Bacteroides, bifidobacteria and Clostridium cluster IV in institutionalized elderly. Exp. Gerontol. 44, 440-446 (2009).
25. Claesson, M. J. et al. Composition, variability, and temporal stability of the intestinal microbiota of the elderly. Proc. Natl Acad. Sci. USA 108 (Suppl. 1), 4586-4591 (2011).
26. Cucchiara, S. et al. The microbiota in inflammatory bowel disease in different age groups. Dig. Dis. 27, 252-258 (2009).
27. Guigoz, Y., Dore, J. &Schiffrin, E. J. The inflammatory status of old age can be nurtured from the intestinal environment. Curr. Opin. Clin. Nutr. Metab. Care 11, 13-20 (2008).
28. Franceschi, C. et al. Inflammaging and anti-inflammaging: a systemic perspective on aging and longevity emerged from studies in humans. Mech. Ageing Dev. 128, 92-105 (2007).
29. Klotz, U. Pharmacokinetics and drug metabolism in the elderly. Drug Metab. Rev. 41, 67-76 (2009).
30. Kuypers, D. R. Immunotherapy in elderly transplant recipients: a guide to clinically significant drug interactions. Drugs Aging 26, 715-737 (2009).
31. Turnheim, K. Drug therapy in the elderly. Exp. Gerontol. 39, 1731-1738 (2004).
32. Shi, S., Morike, K. &Klotz, U. The clinical implications of ageing for rational drug therapy. Eur. J. Clin. Pharmacol. 64, 183-199 (2008).
33. Mangoni, A. A. &Jackson, S. H. Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications. Br. J. Clin. Pharmacol. 57, 6-14 (2004).
34. Tornatore, K. M. et al. Cortisol pharmacodynamics after methylprednisolone administration in young and elderly males. J. Clin. Pharmacol. 37, 304-311 (1997).
35. Stuck, A. E., Frey, B. M. &Frey, F. J. Kinetics of prednisolone and endogenous cortisol suppression in the elderly. Clin. Pharmacol. Ther. 43, 354-362 (1988).
36. Sandborn, W. J. &Hanauer, S. B. Systematic review: the pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis. Aliment. Pharmacol. Ther. 17, 29-42 (2003).
37. Bilyard, K. G., Joseph, E. C. &Metcalf, R. Mesalazine: an overview of key preclinical studies. Scand. J. Gastroenterol. Suppl. 172, 52-55 (1990).
38. So, K. et al. 5-Aminosalicylate (5-ASA) induced nephrotoxicity in inflammatory bowel disease [abstract 638]. Gastroenerology 144 (Suppl. 1), S112 (2013).
39. Gisbert, J. P., Gonzalez-Lama, Y. &Mate, J. 5-Aminosalicylates and renal function in inflammatory bowel disease: a systematic review. Inflamm. Bowel Dis. 13, 629-638 (2007).
40. Lennard, L. The clinical pharmacology of 6-mercaptopurine. Eur. J. Clin. Pharmacol. 43, 329-339 (1992).
41. Sahasranaman, S., Howard, D. &Roy, S. Clinical pharmacology and pharmacogenetics of thiopurines. Eur. J. Clin. Pharmacol. 64, 753-767 (2008).
42. Ha, C. &Dassopoulos, T. Thiopurine therapy in inflammatory bowel disease. Expert Rev. Gastroenterol. Hepatol. 4, 575-588 (2010).
43. Pettersson, B. et al. Differences between children and adults in thiopurine methyltransferase activity and metabolite formation during thiopurine therapy: possible role of concomitant methotrexate. Ther. Drug Monit. 24, 351-358 (2002).
44. Gisbert, J. P. et al. Thiopurine methyltransferase activity in Spain: a study of 14,545 patients. Dig. Dis. Sci. 52, 1262-1269 (2007).
45. Beaugerie, L. et al. Excess risk of lymphoproliferative disorders (LPD) in inflammatory bowel disease (IBD): interim results of the CESAME cohort. Gastroenterology 134, A116-A117 (2008).
46. Beaugerie, L. et al. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet 374, 1617-1625 (2009).
47. Long, M. D. et al. Increased risk for non-melanoma skin cancer in patients with inflammatory bowel disease. Clin. Gastroenterol. Hepatol. 8, 268-274 (2010).
48. Long, M. D. et al. Risk of melanoma and nonmelanoma skin cancer among patients with inflammatory bowel disease. Gastroenterology 143, 390-399 (2012).
49. Gupta, S. et al. Effect of age on molecular signaling of TNF-?-induced apoptosis in human lymphocytes. Mech. Ageing Dev. 124, 503-509 (2003).
50. Hutchinson, W. L. et al. Immunoradiometric assay of circulating C-reactive protein: age-related values in the adult general population. Clin. Chem. 46, 934-938 (2000).
51. Brouwer, A. et al. Cellular aging of the reticuloendothelial system. Arch. Gerontol. Geriatr. 5, 317-324 (1986).
52. Brouwer, A. &Knook, D. L. The reticuloendothelial system and aging: a review. Mech. Ageing Dev. 21, 205-228 (1983).
53. Ordas, I. et al. Anti-TNF monoclonal antibodies in inflammatory bowel disease: pharmacokinetics-based dosing paradigms. Clin. Pharmacol. Ther. 91, 635-646 (2012).
54. Ordas, I., Feagan, B. G. &Sandborn, W. J. Therapeutic drug monitoring of tumor necrosis factor antagonists in inflammatory bowel disease. Clin. Gastroenterol. Hepatol. 10, 1079-1087 (2012).
55. Tinetti, M. E., Bogardus, S. T. Jr &Agostini, J. V. Potential pitfalls of disease-specific guidelines for patients with multiple conditions. N. Engl. J. Med. 351, 2870-2874 (2004).
56. Tooth, L. et al. Weighted multimorbidity indexes predicted mortality, health service use, and health-related quality of life in older women. J. Clin. Epidemiol. 61, 151-159 (2008).
57. Ananthakrishnan, A. N. &McGinley, E. L. Infection-related hospitalizations are associated with increased mortality in patients with inflammatory bowel diseases. J. Crohns Colitis 7, 107-112 (2013).
58. Ha, C., Bayless, T. &Wick, E. Increased incidence of post-operative complications in older inflammatory bowel disease patients having intestinal surgery [abstract 104]. Gastroenterology 142 (Suppl. 1), S25 (2012).
59. Kaplan, G. G. et al. Risk of comorbidities on postoperative outcomes in patients with inflammatory bowel disease. Arch. Surg. 146, 959-964 (2011).
60. Juneja, M. et al. Geriatric inflammatory bowel disease: phenotypic presentation, treatment patterns, nutritional status, outcomes, and comorbidity. Dig. Dis. Sci. 57, 2408-2415 (2012).
61. Frauman, A. G. An overview of the adverse reactions to adrenal corticosteroids. Adverse Drug React. Toxicol. Rev. 15, 203-206 (1996).
62. Ding, T. et al. BSR and BHPR rheumatoid arthritis guidelines on safety of anti-TNF therapies. Rheumatology 49, 2217-2219 (2010).
63. Bernheim, O. et al. The management of immunosuppression in patients with inflammatory bowel disease and cancer. Gut 62, 1523-1528 (2013).
64. Qato, D. M. et al. Use of prescription and over-The-counter medications and dietary supplements among older adults in the United States. JAMA 300, 2867-2878 (2008).
65. Kaufman, D. W. et al. Recent patterns of medication use in the ambulatory adult population of the United States: the Slone survey. JAMA 287, 337-344 (2002).
66. Rochon, P. A. &Gurwitz, J. H. Optimising drug treatment for elderly people: the prescribing cascade. BMJ 315, 1096-1099 (1997).
67. Parian, A. &Ha, C. Severe polypharmacy and major medication interactions are associated with increasing age and comorbidity among inflammatory bowel disease patients [abstract Su1130]. Gastroenerology 144 (Suppl. 1), S11 (2013).
68. Hanlon, J. T. et al. A method for assessing drug therapy appropriateness. J. Clin. Epidemiol. 45, 1045-1051 (1992).
69. Benchimol, E. I. et al. International variation in medication prescription rates among elderly patients with inflammatory bowel disease. J. Crohns Colitis 7, 878-889 (2013).
70. Lichtenstein, G. R., Hanauer, S. B. &Sandborn, W. J. Management of Crohns disease in adults. Am. J. Gastroenterol. 104, 465-483 (2009).
71. Schulte, C. M. Review article: bone disease in inflammatory bowel disease. Aliment. Pharmacol. Ther. 20 (Suppl. 4), 43-49 (2004).
72. Schneeweiss, S. et al. Infliximab and other immunomodulating drugs in patients with inflammatory bowel disease and the risk of serious bacterial infections. Aliment. Pharmacol. Ther. 30, 253-264 (2009).
73. Ha, C. Y. et al. Patients with late-Adult-onset ulcerative colitis have better outcomes than those with early onset disease. Clin. Gastroenterol. Hepatol. 8, 682-687 (2010).
74. Peyrin-Biroulet, L. et al. Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease. Gastroenterology 141, 1621-1628 (2011).
75. Cottone, M. et al. Advanced age is an independent risk factor for severe infections and mortality in patients given anti-Tumor necrosis factor therapy for inflammatory bowel disease. Clin. Gastroenterol. Hepatol. 9, 30-35 (2011).
76. Desai, A. et al. Older age is associated with higher rate of discontinuation of anti-TNF therapy in patients with inflammatory bowel disease. Inflamm. Bowel Dis. 19, 309-315 (2013).
77. Bhushan, A. et al. Association of age with adverse events from biologic therapy in patients with inflammatory bowel disease [abstract 413]. Gastroenterology 138 (Suppl. 1), S62 (2010).
78. Atzeni, F. et al. Long-Term anti-TNF therapy and the risk of serious infections in a cohort of patients with rheumatoid arthritis: comparison of adalimumab, etanercept and infliximab in the GISEA registry. Autoimmun. Rev. 12, 225-229 (2012).
79. Galloway, J. B. et al. Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly. Rheumatology 50, 124-131 (2011).
80. Widdifield, J. et al. Serious infections in a population-based cohort of 86,039 seniors with rheumatoid arthritis. Arthritis Care Res. 65, 353-361 (2013).
81. Colombel, J. F. et al. Infliximab, azathioprine, or combination therapy for Crohns disease. N. Engl. J. Med. 362, 1383-1395 (2010).
82. Panaccione, R. et al. Infliximab, azathioprine, or infliximab + azathioprine for treatment of moderate to severe ulcerative coitis: the UC Success trial. Gastroenerology 140 (Suppl. 1), S134 (2011).
83. Toruner, M. et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology 134, 929-936 (2008).
84. Kornbluth, A. &Sachar, D. B. Ulcerative colitis practice guidelines in adults: American College Of Gastroenterology, Practice Parameters Committee. Am. J. Gastroenterol. 105, 501-523 (2010).
85. Delaney, C. P. et al. Equivalent function, quality of life and pouch survival rates after ileal pouch-Anal anastomosis for indeterminate and ulcerative colitis. Ann. Surg. 236, 43-48 (2002).
86. Delaney, C. P. et al. Functional outcome, quality of life, and complications after ileal pouch-Anal anastomosis in selected septuagenarians. Dis. Colon Rectum 45, 890-894 (2002).
87. Delaney, C. P. et al. Prospective, age-related analysis of surgical results, functional outcome, and quality of life after ileal pouch-Anal anastomosis. Ann. Surg. 238, 221-228 (2003).
88. Ha, C., Bayless, T. &Wick, E. Increased incidence of post-operative complications in older inflammatory bowel disease patients having intestinal surgery [abstract 104]. Gastroenterology 142 (Suppl. 1), S25 (2012).
89. Kaplan, G. G. et al. Impact of hospital volume on postoperative morbidity and mortality following a colectomy for ulcerative colitis. Gastroenterology 134, 680-687 (2008).
90. Page, M. J. et al. Factors affecting surgical risk in elderly patients with inflammatory bowel disease. J. Gastrointest. Surg. 6, 606-613 (2002).
91. Almogy, G. et al. Surgery for ulcerative colitis in elderly persons: changes in indications for surgery and outcome over time. Arch. Surg. 136, 1396-1400 (2001).
92. Ha, C., Bayless, T. &Wick, E. In-hospital morbidity among older inflammatory bowel disease patients having intestinal surgery is predicted by the simplified comorbidity score and functional status [abstract 1009]. Gastroenerology 144 (Suppl. 1), S189 (2013).
93. Ha, C. Y. &Katz, S. Clinical outcomes and management of inflammatory bowel disease in the older patient. Curr. Gastroenterol. Rep. 15, 310 (2013).
94. Pineton de Chambrun, G. et al. Clinical implications of mucosal healing for the management of IBD. Nat. Rev. Gastroenterol. Hepatol. 7, 15-29 (2010).
95. Katz, S., Surawicz, C. &Pardi, D. S. Management of the elderly patients with inflammatory bowel disease: practical considerations. Inflamm. Bowel Dis. 19, 2257-2272 (2013).
96. American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society updated Beers Criteria for potentially inappropriate medication use in older adults. J. Am. Geriatr. Soc. 60, 616-631 (2012).
97. Cosnes, J. et al. Effects of cigarette smoking on the long-Term course of Crohns disease. Gastroenterology 110, 424-431 (1996).
98. Nunes, T. et al. Smoking does influence disease behaviour and impacts the need for therapy in Crohns disease in the biologic era. Aliment. Pharmacol. Ther. 38, 752-760 (2013).
99. Nunes, T. et al. Does smoking influence Crohns disease in the biologic era? The TABACROHN study. Inflamm. Bowel Dis. 19, 23-29 (2013).
100. Cosnes, J. et al. Smoking cessation and the course of Crohns disease: an intervention study. Gastroenterology 120, 1093-1099 (2001).
101. Aldhous, M. C. et al. Smoking habit and load influence age at diagnosis and disease extent in ulcerative colitis. Am. J. Gastroenterol. 102, 589-597 (2007).
102. Boyko, E. J. et al. Risk of ulcerative colitis among former and current cigarette smokers. N. Engl. J. Med. 316, 707-710 (1987).
103. Lunney, P. C. &Leong, R. W. Review article: Ulcerative colitis, smoking and nicotine therapy. Aliment. Pharmacol. Ther. 36, 997-1008 (2012).
104. Sandborn, W. J. et al. Transdermal nicotine for mildly to moderately active ulcerative colitis. A randomized, double-blind, placebo-controlled trial. Ann. Intern. Med. 126, 364-371 (1997).
105. Pullan, R. D. et al. Transdermal nicotine for active ulcerative colitis. N. Engl. J. Med. 330, 811-815 (1994).
106. White-Chu, E. F. et al. Pressure ulcers in long-Term care. Clin. Geriatr. Med. 27, 241-258 (2011).
107. Beldon, P. Incontinence-Associated dermatitis: protecting the older person. Br. J. Nurs. 21, 402-407 (2012).
108. Gensini, G. F., Rostagno, C. &Caciolli, S. Treatment options for acute venous thromboembolism in the older patient. Geriatrics 53, 34-36, 39-40, 46-47 (1998).
109. Grainge, M. J., West, J. &Card, T. R. Venous thromboembolism during active disease and remission in inflammatory bowel disease: a cohort study. Lancet 375, 657-663 (2010).
110. Loudon, C. P. et al. The effects of physical exercise on patients with Crohns disease. Am. J. Gastroenterol. 94, 697-703 (1999).
111. Ng, V. et al. Low-intensity exercise improves quality of life in patients with Crohns disease. Clin. J. Sport Med. 17, 384-388 (2007).
112. Massironi, S. et al. Nutritional deficiencies in inflammatory bowel disease: therapeutic approaches. Clin. Nutr. 32, 904-910 (2013).
113. Calder, P. C. Feeding the immune system. Proc. Nutr. Soc. 72, 299-309 (2013).
114. Melmed, G. Y. Vaccination strategies for patients with inflammatory bowel disease on immunomodulators and biologics. Inflamm. Bowel Dis. 15, 1410-1416 (2009).
115. Zhang, J. et al. Association between vaccination for herpes zoster and risk of herpes zoster infection among older patients with selected immune-mediated diseases. JAMA 308, 43-49 (2012).
116. Moscandrew, M., Mahadevan, U. &Kane, S. General health maintenance in IBD. Inflamm. Bowel Dis. 15, 1399-1409 (2009).
117. Kappelman, M. D. et al. Direct health care costs of Crohns disease and ulcerative colitis in US children and adults. Gastroenterology 135, 1907-1913 (2008).
118. Wolff, J. L., Starfield, B. &Anderson, G. Prevalence, expenditures, and complications of multiple chronic conditions in the elderly. Arch. Intern. Med. 162, 2269-2276 (2002).
119. Centers for Medicare and Medicaid Services. Annual report of the Board of Trustees of the Federal Hospital Insurance and Federal Supplementary Medicine Insurance Trust Fund [online], https://www.cms.gov/Research-Statistics-Data-And- Systems/Statistics-Trends-And-Reports/ReportsTrustFunds/downloads/tr2009.pdf (2009).
120. Centers for Medicare &Medicaid Services. Your guide to Medicare prescription drug coverage [online], http://www.medicare.gov/Pubs/pdf/11109.pdf (2012).
121. Boult, C. et al. Successful models of comprehensive care for older adults with chronic conditions: evidence for the Institute of Medicines retooling for an aging America report. J. Am. Geriatr. Soc. 57, 2328-2337 (2009).
122. Pew Internet. Older adults and internet use [online], http://pewinternet.org/Reports/2012/Older-Adults-And-internet-use.aspx (2012).
123. Boyd, C. M. et al. Guided care for multimorbid older adults. Gerontologist 47, 697-704 (2007).
124. Fisher, H. &McCabe, S. Managing Chronic Conditions for Elderly Adults: the VNS CHOICE Model. Health Care Financ. Rev. 27, 33-45 (2005).